Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To my knowledge they haven't published any data. A number of oncolytic viruses are in trials for rGBM like DNX-2401 (1st gen virus) http://neuro-oncology.oxfordjournals.org/content/16/suppl_3/iii39.2.abstract In addition to this the company behind it and Merck have announced a collaboration using the 1st gen virus with pembrolizumab. I also know they are inserting OX40L http://www.ncbi.nlm.nih.gov/pubmed/19426222 which should improve it http://www.ncbi.nlm.nih.gov/pubmed/22396493/ and could be modifying it in others ways too.
You can also make them better in other ways http://www.ncbi.nlm.nih.gov/pubmed/23730207 http://www.ncbi.nlm.nih.gov/pubmed/27141352
Yeah I saw the 60 minutes show....
Duke looks very close, that one woman being cancer free for 4 years and now in nursing...WoW!!! I know they lost some patients when they increased the dosage of polio virus...explaining that when something works well during trials, SOP is to increase the dosage to see if they can make it work better. Science is slow and painful at times.
Also in the 2nd follow up that I saw they're now looking at combining their method with chemo to address the issue of inflammation, and that its shown promise so far....nice. Duke is so far advanced compared to so many others, and the clock is always ticking.
If Duke is ultimately successful I'll be cheering, even though I don't have any money in play with them...I assume they're private and not pulling in anything close to what Cooper made last year ($15 million?). I think the lead at Duke (freeman? friedman?) should be making double what Coop is based on these results.
see ya back @ three,out :(
unless i learn options and short :)
I think he's at 4+ years of survival now. Amazing in itself.
Don't know if you are familiar with the 60 minutes show on "breakthrough" status drug from polio virus.
http://www.cbsnews.com/news/promising-duke-university-polio-brain-cancer-trial-given-breakthrough-status-60-minutes/
Although this method has some promise, obviously, it has one very major drawback. It is not reversible. Should it cause too much inflammation, the patient will die. Of the 22 patients who have received it 11 are deceased. Some would be, anyway, no doubt, but that is still a high percentage and their end QOL was not good.
Simply stopping the IL-12 for a few days will completely reverse any SAEs.
Yeah I heard of this guy....
He's survived for years after his diagnosis if I'm not mistaken.....has undergone all kinds of treatments and keeps beating the odds....inspirational, I think a lot of people get a cancer diagnosis, and while they fight it, most resign themselves to the outcome and depression sets in which weakens the immune system....while some, like this Peacock guy, he keeps that PMA going and lives far longer because of his attitude.
Glad the trial is working and meeting its primary endpoint, I'd hate to see people trying a therapy or treatment only to find out its toxic or something and kills them. Sadly that does happen, whether a treatment works or not, that requires more complex ph II and a ph III trial obviously. Single arm studies are okay just to prove safety though.
Yes. It's from his blog. The link is in this message which is from Feb. There are newer ones, but this is the one I had handy.
See the blog below just out today from Charles Peacock, the first patient in this ZIOP Glioma Trial of VERY sick patients (Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma)
To even be in this trial you must have RECURRENT or PROGESSIVE Glioblastoma or Grade III/IV Malignant Glioma and must have FAILED previous standard of care anti-tumor treatments including surgery and/or biopsy and chemoradiation (Histologically confirmed supratentorial glioblastoma or other WHO grade III or IV malignant glioma from archival tissue)
Dr Cooper said usually these very sick refractory patients would progress in weeks and die in a few months. All of the patients are now six months since initiating the ZIOP treatment and they are all alive. This is indeed important. FDA will now allow dose escalation and a second cohort. Dr Cooper is extremely encouraged by these results. God Speed to Charles Peacock – what an inspiration.
____________________________________________________________________________
click blue link below to get to his website
There’s No Such Thing As Giving Up
POSTED ON FEBRUARY 3, 2016 BY THEBRAINCHANCERY
https://thebrainchancery.com/about/
Can you link something on that?
Gonna search it now...not doubting you, but need confirmation.
Over a year ago???
The info at clinicaltrials.gov and verified by Ziopharm in February of 2016 has the study start date in June of 2016, that's 11 months ago....and they've only dosed 11 patients, one of whom died but the PR doesn't say when. And we don't know when the first patient was dosed, the PR doesn't say that either....so maybe the first patient was dosed 7 months ago, in the absence of information all one can do is speculate.
But the trial is meeting its primary objective of safety, so that at least is positive. As for survival rates, the collection of data will help determine to what extent Veledimex is responsible and what if any impact Ads-RTS-hIL-12 is having.....
You can't draw cause and effect conclusions from such thin data....although clearly that is what is happening with a lot of people, and maybe that was the intent of the PR.
Like those ads that say: In a recent government survey 9 out of 10 doctors reccommend....
Those type of statements get the attention of the trailer park crowd, but intelligent people ask questions.
1- How recent? Last year, 5 years ago? 10?
2- What government? The Grand Dutchee of Fenwick?
3) Doctors of what? Divinity?
Well, for those patients who have been fortunate enough to have taken the drug, they are still alive. Their odds of that without the drug after having failed all other therapy is close to zero. The abstract was written some months ago so the survival is actually 2-3 time the SOC. The first patient was enrolled nearly a year ago.
You are free to short the stock,and diss it all you want.
I hold a core position and a trading position. My core shares are all free riding now. Coming into ASCO, my trading shares will likely make me a good amount of money again.
You do it your way, I'll do it mine, and I'll hope the drug is successful so that many more can survive the very deadly glioblastoma.
News is only about 6 patients enrolled 6.2 months of longer.....
The full study is supposed to ultimately have an estimated 48 patients according to clincaltrials.gov.....so they're not even 25% there. Citing a median figure is pretty fuzzy as anyone who knows anything about statistics can attest:
http://www.avoidthebag.com/2016/05/ziopharm-news-long-on-hope-vague-on-data.html
Pretty nice PR here.
ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer
— Data to be Presented at the 2016 ASCO Annual Meeting —
— Company to Discuss Results with Regulators after Additional Follow Up —
BOSTON, May 18, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that interim results from the Company's ongoing Phase 1, multi-center dose-escalation study of the gene therapy candidate Ad-RTS-hIL-12 + orally-administered veledimex in patients with recurrent or progressive glioblastoma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 3-7, 2016, at McCormick Place in Chicago, Illinois. Ad-RTS-hIL-12 + veledimex is a novel viral gene therapy candidate for the controlled expression of interleukin 12 (IL-12), a pro-inflammatory cytokine critical for stimulating anti-cancer immune responses.
Glioblastoma is an aggressive primary brain tumor affecting approximately 74,000 people worldwide each year.i, ii Recurrent glioblastoma is an aggressive cancer with one of the lowest 3-year survival rates, at 3%, among all cancers.iii For patients who have experienced multiple recurrences the prognosis is particularly poor, with a median overall survival (OS) of 6-7 months, while OS in patients that have failed temozolomide and bevacizumab, or equivalent salvage chemotherapy, is approximately 3-5 months.iv, v
The primary objective of the study is to determine the safety and tolerability of a single intratumoral Ad-RTS-hIL-12 injection activated upon dosing with oral veledimex. Secondary objectives are to determine the Ad-RTS-hIL-12 + veledimex maximum tolerated dose, the immune responses elicited by Ad-RTS-hIL-12 + veledimex, and assessment of biologic response. Eleven patients with recurrent high-grade gliomas (one with grade III and ten with grade IV) have been treated to date with Ad-RTS-hIL-12 through direct injection into their brain tumors, including seven patients in the first dose cohort (veledimex dosed at 20 mg) and four in the ongoing second dose cohort (veledimex dosed at 40 mg). Veledimex was taken orally to activate the production of IL-12 from the tumor site and stimulate an immune response.
Patients enrolled in this multi-center study have all failed standard therapy, with nine of eleven patients failing additional salvage treatments, for a mean of 2.7 prior lines of therapy in cohort one and 2.0 prior lines in cohort two. No enrollment restrictions were placed on tumor size or location within the supratentorial space. Overall median follow-up for patients enrolled in the trial is 6.2 months with 10 of 11 alive. In the fully-enrolled cohort one, 6 of 7 (86%) patients remain alive with a median follow up of 6.8 months. Enrollment in cohort two is ongoing. Even at its lowest dose, the presence of IL-12 in the bloodstream could be detected, demonstrating that veledimex is bioavailable and crosses the blood brain barrier at sufficient levels to turn on the RheoSwitch (RTS®) and generate IL-12, which could be measured in the blood stream. Furthermore, for those patients that experienced adverse events associated with the treatment, discontinuing veledimex reversed these adverse events.
"Early results observed in the limited number of patients who have been treated with Ad-RTS-hIL-12 + veledimex are very encouraging for a Phase 1 study," said Ennio Antonio Chiocca, M.D., Ph.D., Harvey W. Cushing Professor of Neurosurgery, Department of Surgery, Harvard Medical School, Surgical Director, Center for Neuro-oncology, Dana-Farber Cancer Institute, Chairman, Neurosurgery, Brigham And Women's Hospital and Co-Director, Institute for the Neurosciences, Brigham And Women's Hospital. "Virus-based gene therapy used to stimulate an immunological response in the brain is at the frontier of innovation in treatment, with Ad-RTS-hIL-12 offering perhaps the most controllable approach within this field. In this study, we see encouraging signs of immune activation following the administration of Ad-RTS-hIL-12 + veledimex."
Overall Ad-RTS-hIL-12 + veledimex was well tolerated. All serious adverse events and Grade 3 related toxicities were rapidly reversible upon discontinuation of veledimex. The most common related adverse events included headache, nausea/vomiting, fever, white blood cell/leukocyte count decrease, platelet count decrease and liver function test increase. Four subjects had related serious adverse events.
"Because the brain is a segregated and fragile environment, the ability to turn an immune response on and off is critical to balancing efficacy and tolerability," said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at ZIOPHARM. "As we continue to follow patients with extremely guarded prognoses in this multi-center trial, we hope that these promising early trends in survival are maintained. Our goal, once we reach an optimal dose, will be to promptly initiate registration trial discussions with regulators."
Dr. Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM, added: "Basing our approach on the genetic engineering of adenovirus offers a simpler strategy than replicating viral-therapy options, one that can be rapidly controlled via a drug activating a gene switch, and one that does not rely on intratumoral catheterization. We look forward to testing Ad-RTS-hIL-12 + veledimex not just on its own, but in combination with other immuno-oncology approaches, including checkpoint inhibitors and natural killer cells, in clinical trials that we plan to start this year and next. Our data suggest that patients can take a drug by mouth to activate the immune response in their tumors with exciting results."
Ad-RTS-hIL-12 + veledimex has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of patients with malignant glioma.
ASCO Presentation Details
Title: Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma
Poster Session: Central Nervous System Tumors
Date and Time: Saturday, June 4, 2016 1:00 PM — 4:30 PM CT
Abstract Number: 2052
Poster: #239
Location: Hall A
In addition to the GBM study, a study design for the Company's Phase 1b/2 clinical trial of Ad-RTS-hIL-12 + veledimex in locally advanced or metastatic breast cancer will be outlined at the ASCO annual meeting. The study, which is being conducted at the Memorial Sloan Kettering Cancer Center in New York, is designed to examine the safety, tolerability and efficacy of Ad-RTS-hIL-12 immunotherapy given following standard of care chemotherapy in up to 40 women with locally advanced or metastatic breast cancer of all subtypes. The Company expects that outcome data from this study will be presented at a scientific meeting in the second half of the year.
Title: Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer
Poster Session: Developmental Therapeutics—Immunotherapy
Date and Time: Sunday, June 5, 2016 8:00 AM — 11:30 AM CT
Abstract Number: TPS3097
Poster: #418a
Location: Hall A
Institutions dumping ZIOP....
Used to be over 50% ownership last year, now less than 43%...
http://www.nasdaq.com/symbol/ziop/institutional-holdings
Why did the University of TX sell out?
http://www.avoidthebag.com/2016/05/why-did-univ-of-texas-investment.html
Institution buying
What's up with ZIOP? A buying opportunity here?
Seeking Alpha article....
instablog/15663412-joe_retail/4865294-facts-support-bullish-stance-ziopharm
What Does Ziopharm Oncology Genetic Editing Process Entail? http://marketexclusive.com/what-does-ziopharm-oncology-inc-nasdaqziops-genetic-editing-process-entail/3467/
* * $ZIOP Video Chart 02-24-16 * *
Link to Video - click here to watch the technical chart video
Not if a short squeeze is on. Chart is setup great but STO is crazy high. Maybe a quick pullback to 5.38 and then shorts scramble? Keeping my eye on this one.
A lot of money will need to rotate back into the biotech sector for that to happen. Just saying.... Most of these smallcap and microcap biotech and other "spec stocks" have had their TA charts badly broken by this bear mkt.
If this breaks 7 bucks, we'll see 14 in no time IMO.
ZIOP
Charts looking great. Bottoms is in IMO
ZIOP
Nice PR from 2/9. Especially with that zika scare
ZIOP
ROFL.....
By the way. Just because it is partly cloudy ouside doesn't mean a tornado warning needs to be issued.
Every new bio goes through cycles. So what how long it takes if the science is progressing. Most take in excess of a decade to get to a phase 3, so not abnormal. It often takes 100's of millions to complete the process. That's the purpose of a public comany...to raise money from shareholders. Nothing sleezy or underhanded, it's how the business capitalizes. One can choose to participate or not. Besides that, ZIOP has been printing a lot of green along the way for those willing to take profits and either build larger positions or put it to use elsewhere.
IMO, this is the time to be preparing for opportunity, not worrying about a "possible" event in excess of a year away.
There will be Green in Sixteen IMO. Timing is the key not fear. How each trader/investor reacts when it comes is individual.
The bottom is in on ZIOP, IMO.
I've been watching ZIOP like a hawk for the last couple weeks and despite new IBB and XBI lows, ZIOP has been strong as an ox in that $4.80's range, comfortably above the recent new low of $4.66. In order for this to completely break down and tank it's going to take a major IBB implosion beyond what we've already seen, IMO (or of course bad fundamental news, which is unlikely any time very soon). I've working my way into a position here, as I'm still tentative in this market but another day or two of confirmation I'm betting big. I'll be quick to cut bait if $4.66 is breached, but I'm feeling very confident that the IBB will bounce hard off of another retest of the $247-$250 range, which won't be enough to tank ZIOP below the recent low.
If you know ZIOP, you know you can make 50-100% in a matter of weeks if you catch the right run. My price target for this trade is the $8 range and I think I'll see by the end of the quarter, at the latest. With ZIOP, it could be next week. Having said all that, this market right now is totally f**ked up so I could be way off base lol.
Too bad M. Shekel I isn't running the show on ZIOP and TBIO. We'd be rich by now haha!$!
as predicted gap fill at 6-7 range and than some! lol
Smart move. I think TBIO is around/at bottom. Talked to Kinnon, says analyst give a target of $8. Who knows. I agree with you though. Pump soon sounds right. I wouldn't be surprised to see a merger with a biotech like ZIOP or AMGN. ZIOP $
Ironically....
I recently took out a small position in TBIO....that one imo is due for a pump like ZIOP had last year.
By the end of 2020?
How many shares will they need to sell to survive that long? Get ready for a big RS before then. And then if they fail again like they have before....ouchie. Already in their 2nd decade with an accumlated deficit in excess of 400 million and growing.
ZIOP looking ripe for a move up now$ Will there be an A/M between ZIOP and TBIO? Kirk seems to think so with his latest purchase. ZIOP$/TBIO$
ZIOP is looking good. Will ZIOP acquire TBIO? Kirk has his hands deep in both. Kirk recently bought >4million shares of TBIO @ $1.
Kirk has bought the most shares on the open market and through a single secondary last year and has not sold a single share. MDA didn't sell a single share when ZIOP hit 14 multiple times after drastic pull backs.
They're not in the business of being bagholders.
As for ZIOP not having a single P3 trial.
Let's see how many they will have by 2020. I say multiple trials and a possible forward split after all you shorts one day throw yourselves off a bridge when our MC one day reaches multiple billions.
New blog post on SeekingAlpha....
http://seekingalpha.com/instablog/15663412-joe_retail/4733876-ziopharms-rise-fall-pumpers-gone
I put my opinions on ZIOP out there back in March.....
Its a hyped up bubble, was then and still is now....In their 2nd decade as a public company and still nothing in phase III. A MC of one or two hundred million imo is reasonable on the off chance they might come up with something, but if they fail again even that will be grossly overvalued.
It had a nice run up after the firms underwriting their dilution all put out bullish buy recos. And the shares they gave to Anderson for the partnership deal helped drum up buyers too. Now they've sold enough shares to bagholders to keep the lights on and the pay checks printing through to the end of 2017, maybe a bit longer. I expect to see more dilution in mid to late 2017, maybe even a reverse split depending on how many of the freebee options get added to the pile.
Sal he's the absolute worse. Can't go anywhere without seeing the multitude of different aliases of his spewing the same bs.
And he wants to persecute anyone who is long and informed on the company. I think he may have read a 10K from 2012 once and that's that.
You bash as much as some pump. Then you vanish on any run. At least some pumpers don't budge off of their conviction that ZIOP will one day be a leader in immunoncology.
Hysterically funny. I'm not even a huge fan of ZIOP but this is probably the most ignorant post I've ever read on this site. $100M - $200M? Yes let's value them at less than cash and ignore their $B+ partnership and the fact that competitors trade at MCs in multiple billions. Were you dropped on your head as a child perhaps?
Looks to me like ZIOP is dead for a while....
They raised enough cash in 2015 to get them through for another couple years....then I think it could get pumped again. A fair MC imo is somewhere between 100 and 200 million, on the off chance they might develop something, but if they fail again then even that is inflated.
We need to start that run back to the teens.
Who'd of ever thought we'd be back at these levels. Great for buying and or averaging down. For me it's the latter.
We need to start that run back to the teens.
Who'd of ever thought we'd be back at these levels. Great for buying and or averaging down. For me it's the latter.
Tell me how someone who is in respiratory distress is going to benifit from an inhaler version of this drug?
Have you ever seen in person a junkie who has a respiratory rate of 6-8 and is tetoring on deaths doorstep given Narcan IM.
Stand clear, because most are not that extatic that they were just saved. Most want to kill you for spoiling their high.
Anyway I wish you luck. Please stop spamming me this stock. I'm not in the market for anything right now. If you like to help, please just throw me a life preserver
gap getting filled,5.93 low- but 3's coming to your neighbor hood soon.lol
Followers
|
83
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1231
|
Created
|
08/08/06
|
Type
|
Free
|
Moderators |
http://www.ziopharm.com/
http://finance.yahoo.com/q/h?s=ZIOP
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of a portfolio of in-licensed cancer drugs. It focuses primarily on the licensing and development of proprietary drug candidate families that are related to cancer therapeutics that are already on the market or in development. The company�s product candidates include ZIO-101, ZIO-201, and ZIO-301, which are in phase I and/or II studies. ZIO-101, organic arsenic is in a phase I/II trial in patients with advanced myeloma, as well as a phase I trial in advanced cancers; ZIO-201, stabilized isophosphoramide mustard is in a phase I/II trial in patients with advanced sarcoma, as well as in a phase I trials in advanced cancers; and ZIO-301, an anti-cancer agent that targets mitosis like the taxanes is in a phase I trial. ZIOPHARM was founded in 2003 and is based in New York, New York.
>
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |